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ABSTRACT 
Background: Alzheimer’s disease (AD) is characterized by the dynamic accumulation 
of extracellular amyloid deposits from the interplay between amyloid-β (Aβ) plaques, 
reactive astrocytes and activated microglia. Several immunotherapies against Aβ have 
been shown to reduce amyloid neuropathology. However, the role of the associated 
glia in the recovery process requires clarification. Previously, we described the safety 
and effectiveness in aged domestic canine with cognitive dysfunction syndrome of a 
new active vaccine candidate for the treatment of AD in humans.  
Objective: The aim of this article is to gain a better understand of how immunotherapy 
modifies the amyloid burden and its effects on astroglial and microglial reactivity in 
immunized dogs.  
Methods: In order to achieve this, we compared and quantified amyloid plaques and 
astroglial and microglial reactions in the frontal cortex of unimmunized and immunized 
aged domestic dogs.  
Results: We found amyloid plaques from immunized dogs to be smaller and more 
compact than those from unimmunized dogs. In these new plaques, the associated 
astrocytes were closer and less immunoreactive to S100B. We also found no 
modification in the microglial reaction associated with immunization.  
Conclusion: The anti-Aβ immunotherapy developed in our laboratory modifies the 
equilibrium between soluble and insoluble Aβ in aged dogs in close correlation with 
S100B-negative astrocytosis and microglial reaction.  
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INTRODUCTION 
Alzheimer’s disease (AD) is characterized by the accumulation of intracellular 
neurofibrillary tangles and different forms of extracellular amyloid-β (Aβ) (monomers, 
oligomers, fibrils and plaques) resulting from amyloid precursor protein (APP) 
processing [1,2]. These soluble oligomers, fibrils and amyloid plaques are usually in 
equilibrium between brain tissue, cerebrospinal fluid (CSF) and blood compartments. 
However, the imbalance between Aβ production and clearance in AD leads to the 
accumulation of these amyloid components [3]. Also, changes in the biochemical 
composition of Aβ aggregates oligomers, protofibrils, and fibrils are specifically 
associated with symptomatic occurrence of AD [4]. Thus, the imbalance between 
soluble Aβ production and clearance modifies the amyloid plaque features [5] and the 
glial response [6]. The resulting abundance of amyloid deposits is an interplay between 
plaques of different biochemical composition, reactive astrocytes and activated 
microglia [6–8].  
One of the animals considered to be a good model for research into mild cognitive 
impairment and AD is the aged domestic dog (over eight years old) with cognitive 
dysfunction syndrome (CDS) [9–12]. Since this animal spontaneously develops 
geriatric behavioral changes related to several markers of sporadic AD (soluble Aβ, Aβ 
diffuse plaques and brain atrophy), early AD physiopathology mechanisms and new 
therapeutic targets for innovative therapies can be researched through studies 
performed using CDS dogs [12–14]. Beginning around age eight, the formation and 
maturation of diffuse Aβ deposits are observed by immunostaining in all layers of 
canine cortical grey matter in a characteristic four-stage distribution that correlates with 
the CDS severity degree and astroglial reaction [15–18]. Despite the human studies 
that suggest an association between amyloid plaque stages and the degree of 
microglial activation [20,21], there is still controversy surrounding the activation of 
microglia by diffuse plaques. The contradictory results are probably due to differences 
	   4	  
in the antibodies and lectins used for detection [6,22]. 
Astrocyte overexpression of the beta-subunit of S100 protein (S100B) plays a role in 
the pathogenesis and progression of AD and other neurodegenerative diseases 
through autocrine and paracrine effects on astrocytes, neurons and microglia [23]. In 
AD, most of these S100B-positive astrocytes are closely associated with both diffuse 
and neuritic plaques [24], and their distribution throughout the brain regions mirrors the 
known distribution patterns for Aβ deposits [25]. In CDS dogs, the astrocyte 
proliferation around diffuse plaques was found to be S100B negative, which together 
with the absence of neuritic plaques in the dog brain would suggest an important 
pathogenic role for S100B in the genesis and evolution of AD plaques [20,24].	   
Many anti-Aβ immunotherapies targeting soluble and/or insoluble Aβ [26,27] have been 
tested as ways of preventing or treating AD in animals and humans [28–32] .Due to the 
initial severe adverse effects observed in humans [33,34], further studies focused on 
the design of effective and safe immunotherapy [35,36]. One of these 
immunotherapies, based on a mixture of fibrillar Aβ components, has been developed 
in our laboratory with great effectiveness and complete safety in domestic dogs with 
CDS [37]. In that study, the vaccine led to a very rapid cognitive improvement in all 
treated animals, with no side effects. 
To gain a better understanding of how immunotherapy modifies the amyloid burden 
and its effects on astroglial and microglial reactivity, we quantified amyloid plaques and 
astroglial and microglial reactions in brain samples from unimmunized and immunized 
male and female domestic dogs of different ages and breeds and with different 
cognitive deficits. To avoid the controversy surrounding canine microglia quantification 
with antibodies and lectins, we estimated the microglial reaction by in vitro 
autoradiography of [3H]PK11195 binding to the peripheral benzodiazepine receptor 
(PBR) [38–41].  
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MATERIALS AND METHODS 
Vaccine 
The fibrillar Aβ vaccine was initially prepared with 100 µg of Aβ40 combined with the 
Aβx-40 peptide KLH conjugated. Aβ40 and Aβx-40 peptides were initially dissolved with 
dimethyl sulfoxide (DMSO) (1mg/ml), aliquoted and stored at -20ºC. Once thawed, 
each Aβ peptide was mixed with 1 mg of alum hydroxide suspension (Sigma, Spain). 
After overnight (ON) incubation at 4ºC, a saline solution was added up to a volume of 
1.5 ml prior to the subcutaneous (SC) immunization of the dogs.  
 
Animals  
Twenty-three male and female domestic dogs of different ages and breeds and with 
different cognitive deficits were included in the study (Table 1). All dogs were 
previously classified as non-demented dogs (n=12) or CDS dogs (n=11), depending on 
the score obtained using a validated cognitive test of nine items adapted from the mini-
mental state examination (MMSE) and the Diagnostic and Statistical Manual of Mental 
Disorders (DSM IV) for AD [10,12]. Five of these 23 dogs had been included in a 
previous immunization study performed by our group [37] in which they received six SC 
injections of the fibrillar Aβ vaccine over a period of 51 days and were sacrificed at the 
end of the immunization study after blood extraction (Fig.1, Table 1). One of the 
immunized dogs presented CDS symptoms at the beginning of the immunization 
period.  
All animals were treated according to European legislation on animal handling and 
experimentation (86/609/EU). Procedures were approved by the University of 
Barcelona Ethics Committee, Barcelona, Spain. All efforts were made to minimize 
animal suffering and to use no more than the number of animals required to obtain 
reliable scientific data. 
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Brain tissue preparation  
Animals were euthanatized with an IV overdose of sodium thiopental (75 mg/kg) 
(Thiobarbital, Braun Medical S.A., Spain) and tissue preparation was adapted from 
human brain bank methods [42]. In all cases, donation was formally approved by the 
owner and euthanasia justified for medical reasons, none of which were related to 
immunotherapy. The dog brains were removed immediately following death. Both 
hemispheres were separated and cut into 1-cm thick coronal sections. One 
hemisphere was frozen in powdered dry ice and stored at -80ºC. The other hemisphere 
was fixed by immersion in cold 4% formaldehyde (PFA) diluted in 10 mM phosphate 
buffer (PB, pH 7.4) for four days. After three days of cryoprotection, they were frozen 
on powdered dry ice and kept at −40°C until use. Some liver and spleen samples were 
also collected as tissue control for histological procedures. 
 
Anti-Aβ40 IgGs purification 
pH gradient elution by immunoaffinity column was used for the anti-Aβ40 purification. 
For this, Sepharose powder (Pharmacia, Barcelona, Spain) activated with cyanogen 
bromide and coupled to the Aβ40 peptide (40 amino acid length) was placed into a 
chromatography column (Bio-Rad, CA, USA). After being washed with 10 ml of 100 
mM cold phosphate buffer saline (PBS, pH 7.4), 1 ml dog serum was loaded into the 
column three times. After being washed with 10 ml cold PBS, anti-Aβ40 Igs were eluted 
by pH gradient using firstly 100 mM glycine, pH 2.5 and secondly 100 mM glycine + 4M 
urea, pH 2.5. 200 µl of antibody fractions were collected in Eppendorf tubes containing 
1M Tris, pH 8. Anti-Aβ40 IgGs were detected in each Eppendorf tube using a dot blot 
method. Briefly, antibody samples were loaded on a PVDF membrane (Bio-Rad, 
Madrid, Spain) and incubated for 1 h with biotinylated anti-dog IgG (LifeSpan 
Biosciences, Derio, Spain). Detection was carried out by incubation in 20 mM Tris-
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HCl,- 137 mM NaCl (TBS, pH 7.4) containing 0.03% 3-3’ diaminobenzidine (DAB) and 
0.006% H2O2. Finally, purified antibodies were dialyzed, concentrated to half of the 
volume in 50 mM Tris-HCl, pH 7.4 and stored at -20ºC until use.  
 
Immunohistochemistry 
To detect amyloid plaques and immunoreactive astrocytes on dog sections, 
immunohistochemistry with specific antibodies against Aβ peptide (Dako, Glostrup, 
Denmark), S100B (Dako, Glostrup, Denmark) and Glial Fibrillary Acidic Protein (GFAP) 
(Dako, Glostrup, Denmark) was carried out on 12-µm thick serial sections obtained 
from the PFA-fixed frontal cortex. To detect amyloid plaques on human sections, 
purified dog anti-Aβ40 antibodies from immunized CDS dogs or commercial mouse anti-
Aβ antibodies (Dako, Glostrup, Denmark) were used for the immunohistochemistry. For 
comparisons, immunohistochemistry was carried out in 5-µm thick sections from frontal 
cortex samples of AD human brain. Paraffined fixed brain tissues from AD patients at 
stage II and VI according to the Braak & Braak scale [43] were obtained from the 
Neurological Tissue Bank of the Universitat de Barcelona (Barcelona, Spain).  
Some sections were stained with Perl’s Prussian blue counterstained with neutral red 
to identify hemosiderin deposits resulting from putative microhemorrhages [44]. For 
immunohistochemistry, slices were deparaffined or defrosted and pre-treated in formic 
acid for 2 min. After endogenous peroxidase inhibition for 30 min, the slices were 
incubated with PBS 100mM, pH 7.4, containing 0.5% triton-X100-5% normal goat 
serum (NGS) - 5% Bovine Serum Albumin (BSA) as a blocking agent for 2 h at RT. 
Purified primary antibodies or commercial mouse anti-Aβ antibodies were diluted 
(1/100) with immunobuffer (PBS- 5% triton-X100-1% NGS - 1% BSA) and incubated 
ON at 4ºC. After being washed with PBS, the samples were incubated with 1/4000 
diluted biotinylated anti-dog IgG or 1/100 diluted biotinylated anti-mouse IgG for 2 h. 
After washing, the slices were incubated for 1 h with ExtrAvidin (1/250) and developed 
with 0.03% DAB 0.006% H2O2 in PBS. Some sections were also incubated with anti-
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CD3 (1:300; AbD Serotec, Oxford, UK) followed by biotinylated anti-mouse IgG, for 
immunodetection of infiltrated lymphocytes. 
Double detection of amyloid plaques / astrocytes was performed by sequential 
immunohistochemistry. Amyloid plaques were first stained in black with anti-Aβ 
antibody (diluted 1/100) as described above, and developed by adding NiCl to the 
developing solution to stain astrocytes brown on the same slices. Sections were 
incubated with 1/250 diluted rabbit anti-GFAP antibody or with diluted 1/500 rabbit anti-
S100B antibody detected with biotinylated anti-rabbit IgG (1/500) and developed with 
0.03% DAB-0.006% H2O2 in PBS. To reduce the variability due to immunolabeling 
procedures, for each specific antibody all slices were processed at the same time, 
using the same antibody solutions, and incubation / reaction and developing times. 
Plaques and astrocytes were visualized by optical microscopy (Olympus America Inc., 
NY, USA) and micrographs were taken at 5x and 40x following the same image 
thresholding and acquisition protocol. The number and reactivity of plaques and GFAP-
S100B immunoreactive astrocytes were quantified in dog samples, as previously 
described [20] For this, five semi-randomized micrographs were taken and analyzed 
(Axio-Vision, Carl Zeiss, Germany) in three conditions: 1) to measure the number, area 
and grey color intensity of plaques, we obtained photomicrographs, at a magnification 
of 5x, of the whole frontal cortex area; 2) to measure the number and grey color 
intensity of immunoreactive astrocytes, we obtained photomicrographs, at a 
magnification of 40x, from the frontal cortex; and 3) to estimate the number and grey 
color intensity of immunoreactive astrocytes found within 200 µm of the most external 
part of the plaque, we obtained photomicrographs, at a magnification of 10x, from the 
same five frontal cortex plaques. To improve data reliability, GFAP and S100B 
immunohistochemistry were performed on serial slices and the same semi-randomized 
areas in white matter, and the same semi-randomized plaques were used for all 
parameters analyzed. 
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Thioflavin-T-positive (ThT+) detection of amyloid plaques by purified anti-Aβ40 
IgGs 
ThT+ detection of diffuse amyloid plaques by purified anti-Aβ40 IgGs was carried out on 
5-µm thick slices from the frontal cortex of AD patients at stage II according to the 
Braak & Braak scale [45]. First, Aβ plaques were detected following the 
immunohistochemistry procedure and using purified dog anti-Aβ40 from immunized 
CDS dogs or commercial mouse anti-Aβ antibodies, as described above. The slices 
were then dried in the dark at 4ºC ON, rehydrated and immersed in a solution of 0.05% 
ThT-HCl 0.1M. Afterwards, they were incubated with 1% acetic acid for 20 min, 
washed and mounted with Prolong Antifade reagent (Sigma Aldrich, MO, USA). 
Plaques were visualized by fluorescence microscopy (Carl Zeiss, Germany) and 
photomicrographs were taken at a magnification of 20x.  
 
In vitro autoradiography binding of the [3H]PK11195 to the peripheral 
benzodiazepine receptor (PBR) 
Autoradiographic labeling of PBR, a specific marker of microglia, was performed with 
[3H]PK11195 (NEN, Boston, MA, USA) on 5-µm thick serial sections of frozen 
entorhinal cortex, as described previously [38-40]. Sections were incubated in an ice-
cold 50 mM Tris–HCl solution (pH 7.7) containing 1 nM [3H] PK11195 for 2 h at RT, 
followed by two rinses in 4ºC Tris–HCl buffer for 5 min. Non-specific binding was 
determined in the presence of 1 mM unlabeled PK11195. After rinsing in water, 
sections were dried under a stream of cold air and apposed to Amersham Hyperfilm 
(Amersham, Bucks, UK) for two weeks. Films were developed and analyzed 
densitometrically after calibration with grey scales (3H-microscales; Amersham) using 
the Image-Pro Plus program (MD, USA). The average brain protein content was 8%. 
For each brain, four sections were processed for total binding and two others for non-
specific binding.	   The values obtained for each brain after non-specific binding 
subtraction were averaged and used for statistical comparisons. 
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Statistical analysis. 
Kurtosis and skewness were calculated to verify the normal distribution of data. One-
way ANOVA was performed to compare the plaque, astroglia and microglia parameters 
between the treatment and plaque stage, followed by Fisher’s LSD and Bonferroni 
post-hoc tests. To quantify the association between two variables, a Pearson 
correlation was performed. When normality was not achieved, the values of all groups 
were compared using non-parametric analysis. In these cases, the Kruskal-Wallis test 
(KW) followed by the Mann-Whitney test (MW) were used to compare dependent 
variable groups, and the Spearman correlation was used to quantify the association 
between two variables. In all cases, p<0.05 was considered as significant. Results are 
expressed as a mean ± SEM. All analyses were performed with the programs SPSS 17 
(IBM Spain, Madrid, Spain) and STATGRAPHICS (STSC Inc., Rockville, MD, USA). 
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RESULTS 
Increased cortical microglial reaction in CDS dogs 
Initially, astroglial and microglial reactivity was compared between unimmunized 
control (n = 8) and CDS (n = 10) dogs. To this end, four parameters (number of S100B; 
number of GFAP immunoreactive (IR) astrocytes; grey color intensity of S100B-
positive astrocyte cytoplasm; and binding of [3H]PK11195) were measured in the cortex 
of both groups. In CDS dogs, the number of S100B-IR and GFAP-IR both showed a 
non-significant tendency to increase (Fig. 2A, C), but we found no differences in the 
intensity of S100B labeling (Fig. 2B).  
To study the microglial reaction, [3H]PK11195 autoradiography was performed. 
[3H]PK11195-specific binding showed low levels (between 551 and 1068 fmol/mg prot) 
in the cortex of control dogs, with the lowest values in the internal layers of this area 
(Fig. 4H). Non-specific binding was homogeneous and very low, representing less than 
10% of the total binding. In the cortex of CDS dogs, [3H]PK11195-specific binding was 
29.40% higher when compared with controls (p=0.034). This increase in specific 
labeling was homogeneously distributed in the tissue, and no cluster-associated 
labeling was observed in any layer of the prefrontal cortex (Fig. 5H) 
When data from immunized dogs were included in the study, the intensity of S100B-IR 
showed a non-significant tendency to decrease in all animals. However, no differences 
were found in the number of S100B-IR or GFAP-IR cells or in the [3H]PK11195-specific 
binding (Fig. 2A-D). 
 
Anti-Aβ40 IgGs from immunized dogs recognize diffuse plaques  
Previously, we showed that this vaccine in dogs generates anti-Aβ40 IgGs that cross 
the blood-brain barrier (BBB) and bind to human diffuse plaques [37]. To determine 
whether or not they bind similarly to human neuritic, diffuse and fibrillar amyloid 
plaques in AD stage II and VI, serum from dogs was taken on day 51 of the 
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immunization period. Purified anti-Aβ40 IgGs presented stronger immunoreactivity to 
diffuse plaques than neuritic ones. These antibodies were not IR to ThT+ plaques or 
blood vessels (Fig. 3). A similar study performed with commercial anti-Aβ40 IgGs 
showed an increased IR to neuritic plaques (Fig. 3).  
 
Immunization reduces the size of amyloid plaques and increases their 
compaction 
Prussian blue histochemistry revealed no hemosiderin deposits (Fig. 4A-C) in the 
prefrontal cortex of none of the five immunized dogs, including the one presenting 
CDS. Also, we found no specific CD3-positive staining by immunohistochemistry in 
none of the samples (Fig. 4D-F). 
To determine whether or not the immunization process modifies them, we 
characterized amyloid plaques by immunohistochemistry in three immunized dogs and 
nine control aged animals (older than eight, since young animal brains do not form any 
plaques). We identified two groups of non-immunized dogs, according to the size, 
density and cortical-layer distribution of amyloid plaques, as previously described [12]; 
five dogs presented diffuse amyloid plaques (stage I-II) that had a “cloud-like” aspect, 
covered a large area, were poorly compacted, and were located in layers V-VI of the 
prefrontal cortex (Fig. 5A-C). Four dogs presented more compact amyloid plaques 
(stage III-IV) that were smaller in size, more aggregated and located in layers II-III or 
throughout all layers of the prefrontal cortex (Fig. 5A-C). The three immunized dogs 
presented different specific plaques, which were the smallest in size and had a more 
dense aspect than the stage I-II and stage III-IV plaques (p=0.036 and p=0.033 
respectively; Fig. 5A-C). The plaque distribution in these animals was similar to that of 
the stage III-IV plaques, since they were located in layers II-III or throughout all layers 
of the frontal cortex.  
 
Immunization decreases immunoreactivity to S100B 
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A comparison of the astroglial reaction of dogs classified by amyloid plaque 
morphology showed no difference in the number of S100B-IR and GFAP-IR astrocytes 
(Fig. 5D,F). However, immunized dogs presented a lower intensity of S100B-positive 
astrocyte cytoplasm than the other groups (p=0.016; Fig. 5E). Moreover, both GFAP-IR 
and S100B-IR astrocytes in the prefrontal cortex of immunized dogs presented a lower 
number of cell processes than astrocytes in the prefrontal cortex of non-immunized 
animals amyloid plaques (Fig. 6A,B).  
We also quantified microglial activation by [3H]PK11195 autoradiography. In all animals 
presenting amyloid plaques, the levels of [3H]PK11195-specific binding sites in the 
cortex showed a marked increase when compared to young controls (mean 28.95% 
increase; p=0.016; Fig. 5G,H). We found no immunization effects in that [3H]PK11195-
specific binding increase. 
We then considered amyloid plaques as a unique entity, divided them into three groups 
(stage I-II, stage III-IV and immunized dogs) and analyzed the astrocytes included 
within 200 μm of the plaque perimeter. In the stage III-IV plaque group, the number of 
S100B-IR (p=0.012) and GFAP–IR cells (p=0.031) and the intensity of S100B-IR 
(p<0.001) were lower than the stage I-II plaques (Fig. 6C-E). The plaques from 
immunized dogs presented a similar number of GFAP-IR cells to stage III-IV plaques 
(Fig 6C). However, they presented a lower number of associated S100B-positive 
astrocytes (p=0.050), and the S100B-IR intensity in these cells was the lowest found 
(p=0.001) (Fig. 6 A,B).  
To gain a better understanding of the relationship between astrocytes and plaques, we 
subdivided the 200-µm distance into four 50-µm segments, and calculated the 
percentage of either S100B-IR or GFAP-IR present in each segment (Fig. 6F-H). In the 
stage I-II plaque group, the percentage of S100B–IR cells was similar in all four 
analyzed segments (Fig. 6F), while the furthest-away segment (150-200 µm) presented 
the highest percentage of GFAP-IR cells (pχ2=0.019). In the stage III-IV plaque group, 
the percentage of S100B–IR cells presented a non-significant tendency to increase in 
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the 25-50 µm and 50-100 µm segments when compared to the stage I-II plaques, and 
the same was true of the percentage of GFAP-IR cells (Fig. 6G). In the plaques of 
immunized dogs this tendency to increase reached statistical significance in the 
percentage of GFAP-IR cells included in the 25-50 µm and 50-100µm segments 
(pχ2=0.002; Fig. 6H).  
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DISCUSSION 
This paper presents evidence that the anti-Aβ immunotherapy developed in our 
laboratory [37] modifies the shape and density of Aβ plaques in aged dogs, in close 
correlation with S100B-negative astrocytosis and microglial reaction. We also provide 
data that reinforce the idea that glial cell reactivity is associated with amyloid pathology 
and cognitive dysfunction [17,19,20]. In a previous paper, we showed that this vaccine 
lead to a very rapid cognitive improvement in all treated CDS dogs, with no evident 
side effects [37]. We also found that plasma Aβ40 was increased but remained constant 
in the cerebrospinal fluid of immunized dogs. These modifications were accompanied 
by a 10-fold increased serum anti-Aβ40 IgG [37]. These results established a 
relationship between the grade of CDS and the levels of Aβ peptide in cerebrospinal 
fluid and plasma. We now show that immunization modifies the shape and density of 
Aβ plaques, which argues for a modification of the equilibrium between soluble and 
insoluble Aβ in aged dogs. 
Due to the lack of reliable antibodies available to detect activated microglia in the dog 
brain by immunohistochemistry [46] (and personal observations), the first prominent 
result of this study was the description of an effective method for measuring activated 
microglia in the dog brain. Quantification of PBR concentration by [3H]PK11195-specific 
binding to brain slices has been used extensively to estimate microglial reactivity in 
human and rodent brains [38,47–49]. Similarly, quantification of in vivo radiolabeled-
PK11195 binding to the cerebral PBR is currently used to measure microglial reactivity 
in patients with various pathologies involving neuroinflammation, including AD patients, 
through modern imaging techniques [50–52]. When compared with controls, we herein 
found an increase in [3H]PK11195 binding in the cerebral cortex of CDS dogs, which 
indicates a relationship between microglial activation and canine cognitive 
deterioration. This relationship, also found in human AD [53], is another of the several 
AD hallmarks present in the CDS dog that highlight dogs as a good model for studying 
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the cascade of events that take place with brain amyloid deposition, aging and 
dementia [12].  
We previously established that S100B plays a role in the link between diffuse Aβ 
plaque maturation and astroglial reactivity in the aging dog brain [20]. This time, we 
found no clear association between cognitive decline and an increase in the total 
number of S100B- and GFAP-positive astrocytes. This aspect may represent acute 
events of the animal life that have no relationship with the aging and cognitive process 
[18]. Including dogs with a diverse range of characteristics in the study avoided us 
estimating the possible influence of specific aspects like breed or sex on this result. 
However, our data confirm a relationship between Aβ deposition and canine cognitive 
deficit [15,18], which may be related to alterations in brain function through common 
processes at the early stages of amyloid deposition, as has been suggest for AD 
[54,55].  
We have previously designed and validated in aged dogs the efficacy and safety of a 
new vaccine considered a good candidate for human AD prevention and treatment 
[37]. When we accessed the brains of some of those immunized animals, we were able 
to analyze the effects of the immunization in both the inflammation and the Aβ plaque 
shape and distribution in the brains. Our results argue for a lack microhemorrhages or 
inflammation associated with this immunotherapy. We describe the absence of 
hemosiderin-positive deposits and of CD3-immunopositive cells in the perivascular 
parenchyma. We also found a lack of anti-Aβ antibody binding to blood vessels and a 
homogeneous widespread binding of [3H]PK11195 to prefrontal cortex. These results 
are in line with the lack of side effects found in the clinical follow-up of this same 
immunized animals, and the normality of the frequent plasma and cerebrospinal fluid 
analyses previously published [37]. 
Aged dogs spontaneously develop diffuse plaques that do not fulfill the β-pleated sheet 
(equivalent to AD maturation stages I to IV) and are thioflavin negative, with no 
apparent neuritic component [12]. In all of the immunized dogs, we identified a new 
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group of smaller and more compact amyloid plaques that probably resulted from 
immunization. Aβ immunization induces plaque clearance in both 3×Tg-AD mice and 
humans (See [54] for a review). In dogs, the lack of booster doses in the immunization 
procedure may induce a slow course of Aβ clearance that enables the plaques to be 
completely removed in a few months but prevents side effects. These Aβ aggregates 
may also present differences in the biochemical composition with respect to those of 
non-immunized animals. In human AD, the grade of Aβ phosphorylation is specifically 
associated with symptomatic occurrence of AD [4]. These Aβ phosphorylation 
variations, also found in dispersible Aβ oligomers, protofibrils, and fibrils, may be 
modified by immunization and account, at least in part, for the cognitive deficit 
improvement of immunized dogs. 
In our previous study, we detected anti-Aβ40 IgGs in the cerebrospinal fluid of 
immunized dogs [37], which demonstrates that these antibodies cross the blood-brain 
barrier. We herein found that these anti-Aβ40 IgGs recognize diffuse non-fibrillar 
plaques much more easily than neuritic ones or blood vessels. Thus, antibodies may 
recognize diffuse plaques and activate a neuroinflammatory response that would lead 
to smaller and more compact amyloid plaques with consequences for the soluble-
insoluble Aβ equilibrium between the brain and blood [37]. If this is true, immunized 
dogs should present changes in neuroinflammatory activity when compared with 
control animals. 
In the aged dogs, we found hypertrophic astrocytes overexpressing GFAP and S100B 
generally located just outside the plaque boundary. This distribution is associated with 
plaque stage and proximity and is related to cognitive status [20], as has also been 
described for AD [7,56,57]. In the brains of the immunized aged dogs, we found a 
lower number of reactive astrocytes related to Aβ plaques. These astrocytes were less 
immunoreactive to S100B and GFAP and were grouped more closely to the plaques. 
Activated S100B-IR astrocytes are related to the induction and maintenance of 
dystrophic neurites in amyloid plaques [24,58], due to amyloid toxicity. For that reason, 
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S100B has been considered an important pathogenic factor in the genesis and 
evolution of plaques in AD. The reduced S100B-IR of astrocytes may therefore lead to 
the recovery of dystrophic neurites and the subsequent reduction in amyloid plaque 
processes. Thus, the decrease in S100B overexpression appears in the plaques of 
immunized dogs; these plaques correspond to the more compact stage of plaque 
maturation and present a shorter astrocyte–plaque distance. We previously described 
a correlation between canine graded cognitive deficit, diffuse plaque maturation, and 
S100B-astrocytosis [20]. Thus, astroglial reactivity around the plaque varies according 
to plaque maturation, and S100B positive astrocytes are involved in the more 
advanced stages of maturation and cognitive deficit. Based on that, the reduced 
intensity of S100B-IR, but not GFAP-IR, in astrocytes close to plaques of immunized 
dogs we herein found, may be related with the improved cognitive deficit of these 
immunized CDS animals [37]. Also, the correlation between S100B overexpression 
and the more significant impairments argues for astrocyte participation in autocrine and 
paracrine effects associated with the neurodegenerative process [20,23]. To approach 
this putative relationship, further experiments are needed with a higher number of 
immunized CDS dogs. 
At physiological levels, S100B exerts a protective effect, but when it increases, its 
interactions with other cytokines and microglial cells potentiate the activation of 
microglial, neurodegenerative or apoptosis-inducing effects. Therefore, the absence of 
a microglial reaction specifically associated with diffuse plaques in our study may be 
related to lower plaque–astrocyte interactions and reactivity. Together with the 
absence of microglial cells in AD diffuse plaques [58], our data suggest that the 
involvement of S100B and microglia in the progression of AD does not initiate in the 
very early stages of plaque formation. However, we found an increase in the 
homogeneous widespread binding of [3H]PK11195 in the cerebral cortex of CDS dogs, 
which would suggest that microglia are involved in the initiation and maintenance of 
amyloid pathology [50]. Microglial activity in AD is a controversial subject. While 
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numerous studies in animal models of AD have demonstrated that modulating 
microglial activation can be a powerful strategy for clearing Aβ plaques, it is also 
thought that Aβ might not adequately activate microglia effector functions to clear the 
accumulating amyloid burden from the brain [53]. Our results showed that Aβ 
immunization does not modify the distribution and increase of [3H]PK11195 in CDS 
dogs. However, other changes in microglial activity may occur. As explained for AD 
[60], Aβ immunization specifically increases the phagocytic activity of microglia, which 
would contribute to fibrillar-soluble Aβ clearance and lead to plaque compaction and 
decreased amyloid toxicity. Taken together, all these neuroinflammatory changes may 
contribute, at least in part, to the cognitive improvement of immunized CDS dogs 
observed after several weeks of treatment. 
In conclusion, in this study we demonstrated that the anti-Aβ immunotherapy 
developed in our laboratory modifies the shape and density of plaques in aged dogs in 
close correlation with S100B-negative astrocytosis and microglial reaction. Together 
with our previous study in which we described a cognitive improvement and a shift in 
equilibrium between soluble and insoluble Aβ in immunized dogs, our overall results 
indicate that immunotherapy decreases Aβ toxicity and reaffirm the interest of the anti-
Aβ immunotherapy as a possible treatment for the canine CDS and human AD. Future 
studies would be necessary for a better characterization of the immunization effects on 
Aβ biochemical composition and the interplay between the S100B-positive astrocytes, 
microglia and Aβ burden. 
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FIGURE LEGENDS 
Fig. 1: Immunization procedure. Five dogs received six injections of a fibrillar Aβ 
vaccine over a period of 51 days. Serum from all immunized dogs was collected on day 
51 of the follow-up. Each animal was sacrificed after a different period of time (Table 1)  
 
Fig. 2: Comparison of glial reactivity between non-demented and CDS dogs. The 
number of immunoreactive S100B and GFAP astrocytes (A-C), intensity of S100B-IR in 
the cytoplasm (B) and concentration of specific [3H]PK11195 binding to the PBR (D) 
were measured and compared between non-demented (control) and CDS dogs. We 
observed higher levels of specific [3H]PK11195 binding to the PBR in CDS than in 
control dogs, indicating more activated microglia in these dogs (*, p=0.034). When 
immunized dogs were included in the comparison, only a non-significant tendency for 
the intensity of cytoplasmatic S100B-IR to decrease was observed. 
 
Fig. 3: Detection of human amyloid plaques with purified anti-Aβ IgGs from immunized 
dogs. Immunohistochemistry using commercial anti-Aβ IgGs or purified anti-Aβ IgGs as 
a primary antibody were performed in samples from AD patients in stage II and stage 
VI of the Braak & Braak scale. (A, C) Commercial antibodies can detect neuritic 
plaques (black arrows) and leptomeningeal  blood vessels (arrowheads) in AD stage VI 
samples more effectively. However, (B, D) purified antibodies can detect diffuse 
plaques (black arrows) more effectively, but not leptomeningeal blood vessels 
(arrowheads). Panels E, F show double immunohistochemistry to detect anti-Aβ IgGs 
(red) and ThT+ (blue) and show that fibrillar amyloid plaques were not detected by 
purified anti-Aβ IgGs, while anti-Aβ labeling with commercial antibodies shows them as 
co-localized with ThT+ plaques (pink). Scale bars: 200 µm (A – D); 50 µm (inset in C, D 
and E, F). 
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Fig. 4: Histological study of brain microhemorrhages or lymphocyte infiltration induced 
by immunization. (A-C) Perl’s Prussian blue counterstained with neutral red identified 
hemosiderin deposits in dog liver slices (arrows in A) but not in the perivascular 
prefrontal cortex of immunized control (B) and CDS (C) dogs. (D-F) 
Immunohistochemistry with specific anti-CD3 antibodies stained in dark brown 
lymphocytes in dog spleen slices (D) but not in the prefrontal cortex of immunized 
control (E) and CDS (F) dogs. Asterisks identify blood vessels. Scale bar, 50 µm 
 
Fig. 5: Amyloid plaque detection, classification and relationship with glial reactivity. (A-
C) Study of plaque size and density. Illustrative photomicrographs of amyloid plaques 
from the prefrontal cortex (A), which were classified in: 1) Stages I-II, with large, slightly 
compacted plaques situated in the deeper layers of the prefrontal cortex. 2) Stages III-
IV, with smaller and more compacted plaques situated in layers II-III or throughout all 
layers of the prefrontal cortex. 3) Plaques from immunized dogs, with the smallest and 
most compacted shape. Plaques from immunized dogs were significantly smaller (B) 
and presented increased labeling (C) than stage I-II plaques (*, p=0.036 for the size 
and p=0.033 for the Aβ labeling). (D-G) In accordance with the above classification, 
histograms show quantification of (D) the number of S100B-IR cells, (E) the intensity of 
S100B cytoplasmic staining (*, p=0.016 vs no plaques), (F) the number of GFAP-IR 
cells, and (G) [3H]PK11195-specific binding (*p=0.015 vs no plaques). (H) Illustrative 
photomicrographs of the distribution of specific binding sites for [3H]PK11195 in dog 
brain sections with no amyloid plaques and with stage III-IV plaques. Scale bar, 100 
µm (A), and 3 mm (H)  
 
Fig. 6: Immunoreactive GFAP and S100B astrocytes associated with the amyloid 
plaque. Illustrative photomicrographs of either GFAP-IR or S100B-IR cells in brain 
sections of dogs presenting stage I-II plaques (A) and immunized dogs (B). 
Quantification of the GFAP-IR and S100B-IR cells within 200 µm of the plaque. 
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Histograms show (C) the number of S100B-IR cells, (&, p=0.012; #, p=0.050), (D) the 
intensity of S100B cytoplasmic staining (**, p<0.001, #, p=0.001) and (E) number of 
GFAP-IR cells astrocytes (*, p=0.031). To estimate the differences in the astrocyte-
plaque association, we then divided the distance of 200 µm into four 50-µm segments 
and calculated the percentage of both GFAP-IR and S100B-IR cells (arrows in 
pictures) located in each segment (F-H). GFAP-IR cells associated with plaques from 
immunized dogs (H) showed a non-significant tendency to be located in the closest 
segments when compared to stage I-II (F) and stage III-IV (G) plaques. This tendency 
was not observed for S100B-IR cells. (pχ2=0.019 for 150-200 µm in stage I-II; 
pχ2=0.002 for 25-50 µm, 50-100 µm in plaques from immunized dogs) (5 amyloid 
plaques / sample). 	  
 
Table 1: Dogs included in the study. 
 





Aβ / glia 
IHQ 
1 Beagle 3 Non Demented Unimmunized  0  
2 Cocker 1 Non Demented Unimmunized  0  
3 Poodle 6 Non Demented Unimmunized  0  
4 Mixed 1 Non Demented Unimmunized  0  
5 Mixed 7 Non Demented Unimmunized  0  
6 Yorkshire 8 Non Demented Unimmunizad  0  
7 Schnauzer 8 Non Demented Unimmunizad  I-II + 
8 Poodle 15 Non Demented Unimmunized  I-II + 
9 German Shepherd 10 CDS Unimmunized  I-II + 
10 Poodle 11 CDS Unimmunized  I-II  
11 Mixed 13 CDS Unimmunized  III-IV + 
12 Boxer 15 CDS Unimmunized  I-II + 
13 Mixed 14 CDS Unimmunized  0  
14 Poodle 14 CDS Unimmunized  I-II + 
15 Pekingese 15 CDS Unimmunized  III-IV + 
16 Mixed 16 CDS Unimmunized  III-IV + 
17 Fox Terrier 16 CDS Unimmunized  III-IV  
18 Mixed 20 CDS Unimmunized  III-IV + 
19 Beagle 6 Non Demented Immunized 41 0  
20 Beaqle 8 Non Demented Immunized 31 0  
21 Mixed 12 Non Demented Immunized 40 Immunized + 
22 Mixed 13 Non Demented Immunized 32 Immunized + 
23 Mixed 15 CDS Immunized 38 Immunized + 
 
CDS, cognitive dysfunction síndrome; LTI, live time after immunization; IHQ, immunohistochemistry 	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